Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

Summary

This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.

Timeline

Start

2006-08

Primary completion

2008-05

Completion

2009-05

Drugs

Indications